|
|
 |
|
Viewing report
|
|
|
|
Testicular Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017
GlobalData, May 2011, Pages: 65
Testicular Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, “Testicular Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global testicular cancer market. The report identifies the key trends shaping and driving the global testicular cancer market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global testicular cancer sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData estimates that the global testicular cancer therapeutics market was valued at $91m in 2010, and is forecast to grow at a compound annual growth rate (CAGR) of 3.8% over the next seven years, to reach $118m by 2017. The gradual growth of the market is primarily attributed to the expected continued domination of generics in the testicular cancer therapeutics market, as no disease-modifying molecule is expected to launch during the forecast period of 2017.
Scope
The report provides information on the key drivers and challenges of the testicular cancer therapeutics market. Its scope includes -
- Annualized global testicular cancer therapeutics market revenues data from 2005 to 2010, forecast for seven years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. No molecules are present in Phase III stage of clinical trial.Two molecules are present in Phase II and one is in Phase I. Two molecules are first-in-class and one is me-too. The first-in-class molecules come under the category of cyclin-dependent kinase inhibitors, and the me-too molecule has DNA alkylating activity. The participation of companies in clinical trials for testicular cancer therapeutics is not significant
- Analysis of the current and future competition in the global testicular cancer therapeutics market. The competition in the testicular cancer therapeutics market is weak. The market is dominated by generics such as etoposide, ifosfamide, cisplatin, bleomycin sulfate, gemicitabine, carboplatin and oxaliplatin. ZIOPHARM Oncology Inc. is the only company with a molecule in the clinical pipeline for testicular cancer therapeutics. Very few companies are investing in R&D for testicular cancer.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the testicular cancer therapeutics market.
- Analysis of key recent licensing and partnership agreements in testicular cancer therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global testicular cancer market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global testicular cancer market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global testicular cancer market landscape? – Identify, understand and capitalize.
|
|
|
|
